SCHEMBL2610579

SCHEMBL2610579

CCC(C)N1C(=O)CC(SC)C1=O

nearest known ligand 0.37

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.33
MME P08473 1/20 0.32
HTT P42858 1/20 0.31
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17532415 0.82 ALDH1A1 (0.40) TSHRMMEHTT
SCHEMBL10075279 0.82 MAPT (0.39) TSHRMMELMNA
SCHEMBL12038040 0.80 MME (0.34) TSHRMME
SCHEMBL12509961 0.80
SCHEMBL13313004 0.80 LMNA (0.32) TSHRLMNA
SCHEMBL19598998 0.79 NPC1 (0.32) TSHRHTT
SCHEMBL22434169 0.79 TSHR (0.32) TSHRMME
SCHEMBL19682077 0.79 TSHR (0.34) TSHRMME
SCHEMBL24975427 0.76 ALDH1A1 (0.30)
SCHEMBL12109569 0.76 TSHR (0.33) TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3960767-A2 SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES Novartis AG (CH) 2022-03-02 EP disclosed
US-20120100096-A1 CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS NEKTAR THERAPEUTICS (US) 2012-04-26 US disclosed
US-20110171165-A1 POLYMER CONJUGATES OF OPIOID GROWTH FACTOR PEPTIDES NEKTAR THERAPEUTICS 2011-07-14 US disclosed
US-20110135623-A1 Conjugates of a Cholinesterase Moiety and a Polymer NEKTAR THERAPEUTICS (US) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110135623-A1 Conjugates of a Cholinesterase Moiety and a Polymer BCHE, ACHE, DNPEP TSHR 2764/4885MME 42/4885HTT 2007/4885
US-20110171165-A1 POLYMER CONJUGATES OF OPIOID GROWTH FACTOR PEPTIDES OGFR, OGFRL1, OPRL1 TSHR 1303/4885MME 239/4885HTT 1367/4885
US-20120100096-A1 CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS SLC19A1, FOLR1, SLC46A1 TSHR 1869/4885MME 1086/4885HTT 909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.